| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adherence to minimal experimental requirements for defining extracellular vesicles and their functions
|
Poupardin, Rodolphe
|
|
|
176 |
C |
p.
|
artikel
|
| 2 |
Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics
|
Artzy-Schnirman, Arbel
|
|
|
176 |
C |
p.
|
artikel
|
| 3 |
Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention
|
Krovi, Sai Archana
|
|
|
176 |
C |
p.
|
artikel
|
| 4 |
Anti-aging properties of phytoconstituents and phyto-nanoemulsions and their application in managing aging-related diseases
|
Xue, Feng
|
|
|
176 |
C |
p.
|
artikel
|
| 5 |
Bacteriophage-mediated modulation of microbiota for diseases treatment
|
Zhang, Yu
|
|
|
176 |
C |
p.
|
artikel
|
| 6 |
Bioequivalence assessment of pharmaceutical aerosol products through IVIVC
|
Sandell, Dennis
|
|
|
176 |
C |
p.
|
artikel
|
| 7 |
Biomaterial-based delivery of nucleic acids for tissue regeneration
|
Zhuang, Yaping
|
|
|
176 |
C |
p.
|
artikel
|
| 8 |
Bio-mimic particles for the enhanced vaccinations: Lessons learnt from the natural traits and pathogenic invasion
|
Wu, Sihua
|
|
|
176 |
C |
p.
|
artikel
|
| 9 |
Blood-brain barrier models: Rationale for selection
|
Hanafy, Amira Sayed
|
|
|
176 |
C |
p.
|
artikel
|
| 10 |
Clinical translation of immunomodulatory therapeutics
|
Nash, Amanda
|
|
|
176 |
C |
p.
|
artikel
|
| 11 |
Dennis Sandell (1960–2020)
|
Asking, Lars
|
|
|
176 |
C |
p.
|
artikel
|
| 12 |
Drug delivery carriers with therapeutic functions
|
Cai, Shuting S.
|
|
|
176 |
C |
p.
|
artikel
|
| 13 |
Editorial board members
|
|
|
|
176 |
C |
p.
|
artikel
|
| 14 |
Electrohydrodynamic atomisation driven design and engineering of opportunistic particulate systems for applications in drug delivery, therapeutics and pharmaceutics
|
Ali, Amna
|
|
|
176 |
C |
p.
|
artikel
|
| 15 |
Engineering strategies to capture the biological and biophysical tumor microenvironment in vitro
|
Tan, Matthew L.
|
|
|
176 |
C |
p.
|
artikel
|
| 16 |
Evolution of nanomedicines for the treatment of autoimmune disease: From vehicles for drug delivery to inducers of bystander immunoregulation
|
Yang, Yang
|
|
|
176 |
C |
p.
|
artikel
|
| 17 |
Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs)
|
Ke, Weina
|
|
|
176 |
C |
p.
|
artikel
|
| 18 |
Ferritin nanocage: A promising and designable multi-module platform for constructing dynamic nanoassembly-based drug nanocarrier
|
Zhang, Baoli
|
|
|
176 |
C |
p.
|
artikel
|
| 19 |
Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities
|
Tuleta, Izabela
|
|
|
176 |
C |
p.
|
artikel
|
| 20 |
Formulation strategies for bacteriophages to target intracellular bacterial pathogens
|
Yan, Wei
|
|
|
176 |
C |
p.
|
artikel
|
| 21 |
Harnessing EV communication to restore antitumor immunity
|
Massaro, Crescenzo
|
|
|
176 |
C |
p.
|
artikel
|
| 22 |
Highly branched poly(β-amino ester)s for gene delivery in hereditary skin diseases
|
Zeng, Ming
|
|
|
176 |
C |
p.
|
artikel
|
| 23 |
High-throughput proteomics and AI for cancer biomarker discovery
|
Xiao, Qi
|
|
|
176 |
C |
p.
|
artikel
|
| 24 |
Ingestible devices for studying the gastrointestinal physiology and their application in oral biopharmaceutics
|
Weitschies, Werner
|
|
|
176 |
C |
p.
|
artikel
|
| 25 |
In situ activation of therapeutics through bioorthogonal catalysis
|
Wang, Wenjie
|
|
|
176 |
C |
p.
|
artikel
|
| 26 |
Integration of personalized drug delivery systems into digital health
|
Raijada, Dhara
|
|
|
176 |
C |
p.
|
artikel
|
| 27 |
Interest of extracellular vesicles in regards to lipid nanoparticle based systems for intracellular protein delivery
|
Le Saux, Sarah
|
|
|
176 |
C |
p.
|
artikel
|
| 28 |
Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation
|
Batis, Nikolaos
|
|
|
176 |
C |
p.
|
artikel
|
| 29 |
Liposome composition in drug delivery design, synthesis, characterization, and clinical application
|
Large, Danielle E.
|
|
|
176 |
C |
p.
|
artikel
|
| 30 |
Mucosal drug delivery and 3D printing technologies: A focus on special patient populations
|
Karavasili, Christina
|
|
|
176 |
C |
p.
|
artikel
|
| 31 |
Multifaceted role of phyto-derived polyphenols in nanodrug delivery systems
|
Chen, Zhejie
|
|
|
176 |
C |
p.
|
artikel
|
| 32 |
Nanotechnologies for the delivery of biologicals: Historical perspective and current landscape
|
Durán-Lobato, Matilde
|
|
|
176 |
C |
p.
|
artikel
|
| 33 |
Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment
|
Xu, Xiaoyu
|
|
|
176 |
C |
p.
|
artikel
|
| 34 |
Nanotechnology-empowered vaccine delivery for enhancing CD8+ T cells-mediated cellular immunity
|
Liu, Guangna
|
|
|
176 |
C |
p.
|
artikel
|
| 35 |
Natural killer (NK) cell-based immunotherapies and the many faces of NK cell memory: A look into how nanoparticles enhance NK cell activity
|
Mikelez-Alonso, Idoia
|
|
|
176 |
C |
p.
|
artikel
|
| 36 |
Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases
|
Zu, Menghang
|
|
|
176 |
C |
p.
|
artikel
|
| 37 |
Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis
|
Kumar, Santosh
|
|
|
176 |
C |
p.
|
artikel
|
| 38 |
Phytonanomaterials as therapeutic agents and drug delivery carriers
|
Xie, Ying
|
|
|
176 |
C |
p.
|
artikel
|
| 39 |
Probiotic engineering strategies for the heterologous production of antimicrobial peptides
|
Mejía-Pitta, Adriana
|
|
|
176 |
C |
p.
|
artikel
|
| 40 |
Prophylactic vaccine delivery systems against epidemic infectious diseases
|
Pan, Chao
|
|
|
176 |
C |
p.
|
artikel
|
| 41 |
Reconstructing the tumor architecture into organoids
|
Luo, Zhimin
|
|
|
176 |
C |
p.
|
artikel
|
| 42 |
Sensing technologies and experimental platforms for the characterization of advanced oral drug delivery systems
|
Okeyo, Peter Ouma
|
|
|
176 |
C |
p.
|
artikel
|
| 43 |
Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across
|
Minnaert, An-Katrien
|
|
|
176 |
C |
p.
|
artikel
|
| 44 |
Supercritical fluid (SCF)-assisted fabrication of carrier-free drugs: An eco-friendly welcome to active pharmaceutical ingredients (APIs)
|
Kankala, Ranjith Kumar
|
|
|
176 |
C |
p.
|
artikel
|
| 45 |
Technological advances towards extracellular vesicles mass production
|
Grangier, Alice
|
|
|
176 |
C |
p.
|
artikel
|
| 46 |
The clinical role of host and bacterial-derived extracellular vesicles in pneumonia
|
Jung, Anna Lena
|
|
|
176 |
C |
p.
|
artikel
|
| 47 |
The importance of nanoparticle physicochemical characterization for immunology research: What we learned and what we still need to understand
|
Clogston, Jeffrey D.
|
|
|
176 |
C |
p.
|
artikel
|
| 48 |
Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis
|
Kumar, Virender
|
|
|
176 |
C |
p.
|
artikel
|
| 49 |
The role of the HBCU pipeline in diversifying the STEM workforce: Training the next generation of drug delivery researchers
|
Smith, Kalynda C.
|
|
|
176 |
C |
p.
|
artikel
|
| 50 |
Women-specific routes of administration for drugs: A critical overview
|
das Neves, José
|
|
|
176 |
C |
p.
|
artikel
|
| 51 |
Zebrafish as a preclinical model for Extracellular Vesicle-based therapeutic development
|
Androuin, Alexandre
|
|
|
176 |
C |
p.
|
artikel
|
Tijdschrift beschrijving